XORTX Therapeutics XRTX
NASDAQ XRTX
$0.97 +0.04 (+4.16%)
At close: Oct 22, 2026 · 4:00 PM EDT

XORTX Therapeutics (XRTX) Cash from Operations (2022)

Updated

XORTX Therapeutics' Cash from Operations was -$2.77 million in the year ended Dec 31, 2025, compared with -$3.68 million a year earlier.

Analysis

XORTX Therapeutics (XRTX) Cash from Operations (2022) Analysis & Trends

From the year ended Dec 31, 2019 onward, XORTX Therapeutics has reported Cash from Operations for 7 years.

  • The figure for the year ended Dec 31, 2025 marks the highest annual Cash from Operations since the year ended Dec 31, 2020.
  • Per Business Quant data, Cash from Operations in earlier years was -$3.68 million in the year ended Dec 31, 2024, -$6.58 million in the year ended Dec 31, 2023, -$8.17 million in the year ended Dec 31, 2022 and -$4.8 million in the year ended Dec 31, 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 10.69 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 7.72 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 3.44 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn 5.37 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 5.88 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 2.87 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 4.00 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn 3.57 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn 835.00 Mn
10 XORTX Therapeutics 883,293.50 -2.42 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 -3.80 Mn
Sep 30, 2022 -951,535.92
API Access

XORTX Therapeutics Cash from Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-operations&ticker=XRTX&period=max&api_key=YOUR_API_KEY